Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00612170 · ClinicalTrials.gov registry record · Phase 3
A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,129
- Enrollment target
NCT00612170: Completed Phase 3 study, sponsored by Pfizer.
NCT00612170 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,129 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (46% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00612170, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,129 participants
- Enrollment target
Study Summary
This is a study to investigate the effectiveness and safety of \[S,S\]-Reboxetine in relieving the symptoms of Fibromyalgia in patients. A previous study demonstrated clinically meaningful treatment effects in fibromyalgia, based on pain and functional endpoints.
Interventions
- DRUG Placebo
- DRUG [S,S]-Reboxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,129 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
What the finished NCT00612170 record still lists
NCT00612170 is an interventional study that assigns participants to a tested intervention. Its 1,129 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (46% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00612170 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00612170 about?
NCT00612170 is a clinical study titled "A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.". This is a study to investigate the effectiveness and safety of \[S,S\]-Reboxetine in relieving the symptoms of Fibromyalgia in patients. A previous study demonstrated clinically meaningful treatment effects in fibromyalgia, based on pain and functional endpoints.
What is the current status of trial NCT00612170?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,129 participants. The study started on 2007-12. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00612170?
The interventions under investigation include: Placebo (DRUG), [S,S]-Reboxetine (DRUG).
Who is sponsoring clinical trial NCT00612170?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00612170's enrollment target sits among peer trials
1,129 247th of 2000 higher than 1,754 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06445062 · 1,130 participants · Phase 1
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- NCT06746129 · 1,126 participants · Phase 3
Cleavage-stage Versus Blastocyst-stage Embryo Transfer in IVF Patients With Few Embryos
- NCT04421768 · 1,125 participants · NA
Effects of Systematic Cervical Exam Training on Labor and Delivery Care
- NCT06895148 · 1,125 participants · NA
ADHERE-LPV Advancing Delivery of High-Quality Evidence-Based Respiratory Efforts in Lung-Protective Ventilation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia